Investigational drug · Phase 2
HS_SW01 cells
Also called: HS_SW01
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ankylosing Spondylitis, Primary Ovarian Insufficiency (Poi), Systemic Sclerosis (SSc).
Phase 2Last checked: Nov 20, 2026Latest source record: Apr 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "HS_SW01 cells"
First trial start
2026
Apr 10, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HS_SW01 cells", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ankylosing Spondylitis
- Primary Ovarian Insufficiency (Poi)
- Systemic Sclerosis (SSc)
Approved drugs for the same conditions: Ankylosing spondylitis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "HS_SW01 cells" as an intervention, largest first.
- Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Primary Ovarian InsufficiencyNot yet recruiting
Shenzhen Huishan Biotechnology Co., Ltd.Industry
NCT07551895 · 21 participants (planned) · Start Apr 15, 2026 · Primary completion Dec 31, 2027
Drug: HS_SW01 cells injection; HS_SW01 cells injection and 1 more · For: Primary Ovarian Insufficiency (Poi)
- Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Systemic SclerosisNot yet recruiting
Shenzhen Huishan Biotechnology Co., Ltd.Industry
NCT07535931 · 21 participants (planned) · Start Apr 10, 2026 · Primary completion Dec 31, 2027
Drug: HS_SW01 cells injection; HS_SW01 cells injection and 1 more · For: Systemic Sclerosis (SSc)
- A Phase I/Ⅱ Clinical Trial for Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Ankylosing SpondylitisNot yet recruiting
Shenzhen Huishan Biotechnology Co., Ltd.Industry
NCT07534644 · 18 participants (planned) · Start Apr 10, 2026 · Primary completion Dec 31, 2027
Drug: HS_SW01 cells injection · For: Ankylosing Spondylitis
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Ankylosing Spondylitis
- Jaktinib HydrochloridePhase 34 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Atopic Dermatitis, Ankylosing Spondylitis
- LNK01001Phase 33 trials
Lynk Pharmaceuticals Co., Ltd · Ankylosing Spondylitis, Atopic Dermatitis, Rheumatoid Arthritis
- AK111Phase 32 trials
Akeso · Psoriasis, Skin Diseases, Ankylosing Spondylitis
- vilamakitugXB2001, NatrunixPhase 22 trials
XBiotech, Inc. · Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpA
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.